Healthcare IT Today

DECEMBER 6, 2024

As precision medicine becomes more nuanced and complex, biopharmaceutical companies are increasingly turning to AI to enhance the utility, performance, and scalability of computational pathology analyses for drug development and diagnostics. Originally announced October 29th, 2024 More information at htgf.de.

Life Science 77

Life Science Drug Development Health IT Healthcare IT 77

Digital Health Global

JANUARY 28, 2025

a leading provider of clinical development technology, today announced new data from the Tufts Center for the Study of Drug Development (CSDD)s PACT Consortium links decentralized clinical trial (DCT) approaches to notably higher participation rates across multiple demographic groups. 5000 in 2024. PALO ALTO, Calif.–(BUSINESS

Drug Development 88

Drug Development Pharmaceuticals Digital Health 88

Digital Health Global

JANUARY 29, 2025

a leading provider of clinical development technology, today announced new data from the Tufts Center for the Study of Drug Development (CSDD)s PACT Consortium linking decentralized clinical trial (DCT) approaches to notably higher proportional representation among select demographic subgroups. 5000 in 2024.

Drug Development 88

Drug Development Pharmaceuticals Digital Health 88

Lloyd Price

SEPTEMBER 16, 2024

Exec Summary: The Morgan Stanley 22nd Annual Global Healthcare Conference was held in September 2024. Artificial Intelligence (AI) and Machine Learning (ML): AI and ML are revolutionising the healthcare industry, from drug discovery to patient diagnosis and treatment. Key themes discussed during the conference included: 1.

Digital Health 64

Digital Health Drug Development healthcare technology Leadership 64

Digital Health Global

JANUARY 25, 2024

Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism. from January 23-25, 2024. Debiopharm is headquartered in Lausanne, Switzerland, and will be presenting at the 7th Annual DDR Inhibition Conference in Boston from January 29-30, 2024.

Drug Development 88

Drug Development Digital Health 88

Digital Health Global

APRIL 5, 2024

growth between 2023 to 2024. Furthermore, the industry witnessed a decline in the average return on investment (ROI) for R&D to as low as 1.2%, and the peak sales per asset valued just above $350 million, indicating a need to build more efficient drug development processes with the implementation of newer technologies.

Drug Development 88

Drug Development Pharmaceuticals Digital Health Health Technology 88

Lloyd Price

AUGUST 7, 2024

Medical Record Automation (MRA) has undeniably emerged as a critical subsector within HealthTech in 2024. Enhanced Research: Automated data analysis can accelerate medical research and drug development. Population Health Management: Analyzing large datasets can help identify trends and develop targeted prevention strategies.

Interoperability 60

Interoperability Leadership Drug Development EHR 60

Digital Health Global

JANUARY 8, 2024

In 2024, expect to see more innovative technologies and new ways of delivering streamlined, patient-centric trials from Medable.” Medable, which ranked in the top 8% of software companies on the 2023 Inc. Medable, which ranked in the top 8% of software companies on the 2023 Inc.

Life Science 88

Life Science Drug Development Pharmaceuticals HIPAA 88

Lloyd Price

FEBRUARY 22, 2024

Reasons for Low Investment: High regulatory hurdles: Drug development for pain is historically challenging with a high failure rate due to complex pain mechanisms and stringent regulatory requirements. While 2023 data isn't fully available, some reports suggest a slight uptick in investment, but the disparity persists.

Pain management 56

Pain management Mental health Telehealth healthcare technology 56

Digital Health Global

JANUARY 31, 2024

A Tufts Center for the Study of Drug Development study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment of on average of $500K in Phase 2 and $1.5M in Phase 3.

Health science 88

Health science Drug Development Digital Health Patient Experience 88

DrKumo Remote Patient Monitoring

FEBRUARY 29, 2024

What are the benefits of AI in drug development? AI accelerates drug development by rapidly analyzing vast datasets to identify potential therapeutic compounds and predict their effectiveness, significantly reducing the time and cost associated with bringing new drugs to market. Contact us today!

Mental health 40

Mental health Drug Development Health Data Patient Experience 40

Lloyd Price

FEBRUARY 18, 2024

Drug development: Pharmaceutical companies like Novo Nordisk, Eli Lilly, and AstraZeneca led the development and commercialization of GLP-1 RAs. How will GLP-1s potentially affect HealthTech share prices in 2024? This sentiment might persist in 2024, further impacting share prices.

Pharmaceuticals 60

Pharmaceuticals healthcare technology Leadership Drug Development 60

Lloyd Price

APRIL 29, 2024

Exec Summary: On the 24th April 2024, members of the European Parliament (MEPs) approved the creation of the European Health Data Space (EHDS). The EHDS is still under development, but a political agreement between the European Parliament and the Council was reached in April 2024.

Health Data 64

Health Data healthcare technology Digital Health Leadership 64

Digital Health Global

OCTOBER 17, 2024

This flagship initiative is a natural extension of prior WBF forums in which the importance of determining sex and gender differences has been discussed with the entire healthcare ecosystem – policymakers, academia, patient association, drug developers, regulators and funding agencies. Global Burden of Disease Study 2021 (GBD 2021).

Drug Development 88

Drug Development Mental health Nursing Digital Health 88

Healthcare IT Today

JANUARY 17, 2024

As we kick off 2024, we wanted to start the new year with a series of 2024 Health IT predictions. 2024 will likely see continued hype regarding A.I. True advancements will be seen in predictive algorithms for drug benefits and toxicities, particularly in cancer treatment. in medicine in all aspects.

Health IT 103

Health IT Mental health Interoperability Patient Experience 103

Healthcare IT Today

APRIL 25, 2024

This contextual understanding is pivotal in drug development decision-making, revealing patient selection insights unpredictable using today’s tools to maximize the value of both approved medicines and drugs in development.” . Originally announced March 13th, 2024

Drug Development 126

Drug Development healthcare technology Health IT Healthcare IT 126

Healthcare IT Today

DECEMBER 1, 2024

Sales and Company News Clinical trial optimization company PhaseV announced seven global pharma companies are using its machine learning platform for drug development. AI-powered value-based care platform Navina joined FLAACOs , the Florida Association of Accountable Care Organizations, as a business partner.

eCare 94

eCare RCM Drug Development Accountable Care 94

Digital Health Wire

DECEMBER 18, 2024

The task force started by highlighting AIs potential across a long list of use cases, which could have been the tracklist for healthcares greatest hits of 2024: Drug Development – 300+ drug applications contained AI components this year. Ambient AI – Burnout is bad. Patient time is good.

Leadership 52

Leadership Drug Development Interoperability Digital Health 52